Although the efficiency of anti-PD-1/PD-L1 has been clearly addressed in melanoma and NSCLC, the results from other types of cancers are less promising, and the response of individuals to ICB varies, which suggested the effects of other factors including genetics, environment, behavior, and even gut microbiota on the therapeutical efficiency of ICB (38). The gene discussed is CD274; the disease is non-small cell lung carcinoma.